John M. Evans, CEO at Beam Therapeutics Inc. (BEAM), sold 36,204 shares at $32.13 ($1.2M) on 2024-04-01, disclosed to the SEC on 2024-04-03.
Scheduled sale ($1.2M) by CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.13 | 18,102 | $582K | 50.0% |
| 2 | $32.13 | 18,102 | $582K | 50.0% |
| Total | $32.13 avg | 36,204 | $1.2M | 100% |
| Filing → |
| BEAM | SELL | 2026-04-01 | $1.1M | — | Filing → |
| BEAM | SELL | 2026-02-02 | $2.8M | — | Filing → |
| BEAM | SELL | 2025-10-03 | $1.2M | — | Filing → |